AMPH AMPHASTAR PHARMACEUTICALS IN revenue, earnings and financials

For the quarter ended June 30, 2026, AMPHASTAR PHARMACEUTICALS IN reported revenue of $184M (up 5.4% from a year earlier), net income of $30.3M and diluted EPS of $0.67; over the last four quarters revenue was $730M and net income $78.5M; for the fiscal year ended December 2025 revenue was $720M, down 1.7% on the year before.

AMPH annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $720M, gross profit $356M, operating income $140M, net income $98.1M (margin 13.6%), EPS $2.03
• Fiscal year ended Dec 2024: revenue $732M, gross profit $374M, operating income $205M, net income $160M (margin 21.8%), EPS $3.06
• Fiscal year ended Dec 2023: revenue $644M, gross profit $351M, operating income $197M, net income $138M (margin 21.3%), EPS $2.60
• Fiscal year ended Dec 2022: revenue $499M, gross profit $249M, operating income $107M, net income $91.4M (margin 18.3%), EPS $1.74
• Fiscal year ended Dec 2021: revenue $438M, gross profit $200M, operating income $69.9M, net income $62.1M (margin 14.2%), EPS $1.25

AMPH quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $184M (up 5.4% year over year), net income $30.3M, EPS $0.67
• Quarter ended Mar 31, 2026: revenue $171M (up 0.4% year over year), net income $6.42M, EPS $0.14
• Quarter ended Dec 31, 2025 (from the annual report): revenue $183M (down 1.8% year over year), net income $24.4M, EPS $0.51
• Quarter ended Sep 30, 2025: revenue $192M (up 0.3% year over year), net income $17.4M, EPS $0.37
• Quarter ended Jun 30, 2025: revenue $174M (down 4.4% year over year), net income $31.0M, EPS $0.64
• Quarter ended Mar 31, 2025: revenue $171M (down 0.8% year over year), net income $25.3M, EPS $0.51
• Quarter ended Dec 31, 2024 (from the annual report): revenue $187M (up 4.7% year over year), net income $38.0M, EPS $0.74
• Quarter ended Sep 30, 2024: revenue $191M (up 5.9% year over year), net income $40.4M, EPS $0.78
• Quarter ended Jun 30, 2024: revenue $182M (up 25.2% year over year), net income $37.9M, EPS $0.73
• Quarter ended Mar 31, 2024: revenue $172M (up 22.7% year over year), net income $43.2M, EPS $0.81
• Quarter ended Dec 31, 2023 (from the annual report): revenue $178M (up 31.9% year over year), net income $36.2M, EPS $0.70
• Quarter ended Sep 30, 2023: revenue $181M (up 50.3% year over year), net income $49.2M, EPS $0.91
• Quarter ended Jun 30, 2023: revenue $146M (up 18.0% year over year), net income $26.1M, EPS $0.49
• Quarter ended Mar 31, 2023: revenue $140M (up 16.3% year over year), net income $26.0M, EPS $0.50
• Quarter ended Dec 31, 2022 (from the annual report): revenue $135M (up 11.7% year over year), net income $33.9M, EPS $0.64
• Quarter ended Sep 30, 2022: revenue $120M (up 7.1% year over year), net income $15.9M, EPS $0.30
• Quarter ended Jun 30, 2022: revenue $123M (up 21.4% year over year), net income $17.3M, EPS $0.33
• Quarter ended Mar 31, 2022: revenue $120M (up 16.8% year over year), net income $24.3M, EPS $0.47
• Quarter ended Dec 31, 2021 (from the annual report): revenue $121M, net income $19.8M, EPS $0.40
• Quarter ended Sep 30, 2021: revenue $112M, net income $29.5M, EPS $0.59

AMPH cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $156M, share buybacks $75.6M
• Fiscal year ended Dec 2024: operating cash flow $213M, share buybacks $85.5M
• Fiscal year ended Dec 2023: operating cash flow $184M, share buybacks $58.1M
• Fiscal year ended Dec 2022: operating cash flow $89.2M, share buybacks $39.9M
• Fiscal year ended Dec 2021: operating cash flow $98.0M, share buybacks $28.9M

AMPH balance sheet

• Jun 30, 2026: cash $224M, total assets $1.74B, total liabilities $976M, shareholders' equity n/a
• Mar 31, 2026: cash $171M, total assets $1.65B, total liabilities $875M, shareholders' equity n/a
• Dec 31, 2025: cash $170M, total assets $1.63B, total liabilities $840M, shareholders' equity n/a, long-term debt $620M
• Sep 30, 2025: cash $216M, total assets $1.67B, total liabilities $889M, shareholders' equity n/a
• Jun 30, 2025: cash $188M, total assets $1.62B, total liabilities $858M, shareholders' equity n/a
• Mar 31, 2025: cash $183M, total assets $1.63B, total liabilities $875M, shareholders' equity n/a
• Dec 31, 2024: cash $152M, total assets $1.58B, total liabilities $845M, shareholders' equity n/a, long-term debt $614M
• Sep 30, 2024: cash $192M, total assets $1.55B, total liabilities $818M, shareholders' equity n/a

What is AMPH's revenue?

AMPHASTAR PHARMACEUTICALS IN reported $730M of revenue over its last four quarters, through June 30, 2026.

Is AMPH profitable?

Yes. AMPHASTAR PHARMACEUTICALS IN earned $78.5M over the last four quarters.

What is AMPH's EPS?

Diluted earnings per share over the last four quarters were $1.69; $0.67 in the latest quarter.

AMPH ownership and insider trades · All stocks